NKT cell costimulation: experimental progress and therapeutic promise
Invariant natural killer T ( i NKT) cells are innate lymphocytes with unique specificity for glycolipid antigens and remarkable immunomodulatory properties. The role of costimulatory interactions in i NKT cell responses has recently come under scrutiny. Although i NKT cells and their prototype glyco...
Gespeichert in:
| Veröffentlicht in: | Trends in molecular medicine 2011-02, Vol.17 (2), p.65-77 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 2 |
| container_start_page | 65 |
| container_title | Trends in molecular medicine |
| container_volume | 17 |
| creator | van den Heuvel, Marianne J Garg, Nitan Van Kaer, Luc Haeryfar, S.M. Mansour |
| description | Invariant natural killer T ( i NKT) cells are innate lymphocytes with unique specificity for glycolipid antigens and remarkable immunomodulatory properties. The role of costimulatory interactions in i NKT cell responses has recently come under scrutiny. Although i NKT cells and their prototype glycolipid agonist α-galactosylceramide (α-GalCer) have shown promise in several clinical trials conducted in patients with cancer or viral diseases, current i NKT cell-based therapies are far from effective. The concomitant targeting of T cell receptors (TCRs) and costimulatory molecules on i NKT cells represents an exciting new opportunity to optimize such therapeutic approaches. Here, we review recent advances in our understanding of i NKT cell costimulation and discuss potential treatment modalities based on the responsiveness of i NKT cells to disease-tailored glycolipids and select costimulatory ligands. |
| doi_str_mv | 10.1016/j.molmed.2010.10.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3616392</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1471491410001619</els_id><sourcerecordid>907160221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-4f6f696e68730def0ed49bdf3d8c62b487f76270df692a789f8dd7576ebc290e3</originalsourceid><addsrcrecordid>eNqFUk1v1DAQtRCIlsI_QCg3TruMncQfHJBQVQpqBQeKxM3y2pPWixMHO6nov6_DtsvHpSdbM2-e3_MbQl5SWFOg_M123cfQo1sz-F1aA4hH5JA2gq4apb4_3t9pc0Ce5bwFoK0Q8ik5YBSkUACH5OTz2UVlMYTKxjz5fg5m8nF4W-GvEZPvcZhMqMYULxPmXJnBVdMVJjPiPHm7NHqf8Tl50pmQ8cXdeUS-fTi5OP64Ov9y-un4_fnKto2aVk3HO644cilqcNgBukZtXFc7aTnbNFJ0gjMBrqCYEVJ10jnRCo4byxRgfUTe7XjHeVOs26IumaDHItSkGx2N1_92Bn-lL-O1rjnltWKF4PUdQYo_Z8yTLvIX-2bAOGetQFAOjNEHkbKlomUgF2SzQ9oUc07Y7fVQ0EtUeqt3UeklqqVaoipjr_72sh-6z-aPWSw_eu0x6Ww9DhadT2gn7aJ_6IX_CWzwg7cm_MAbzNs4p6GkpanOTIP-uqzLsi0UyqZwqupbecm9aQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>851752081</pqid></control><display><type>article</type><title>NKT cell costimulation: experimental progress and therapeutic promise</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>van den Heuvel, Marianne J ; Garg, Nitan ; Van Kaer, Luc ; Haeryfar, S.M. Mansour</creator><creatorcontrib>van den Heuvel, Marianne J ; Garg, Nitan ; Van Kaer, Luc ; Haeryfar, S.M. Mansour</creatorcontrib><description>Invariant natural killer T ( i NKT) cells are innate lymphocytes with unique specificity for glycolipid antigens and remarkable immunomodulatory properties. The role of costimulatory interactions in i NKT cell responses has recently come under scrutiny. Although i NKT cells and their prototype glycolipid agonist α-galactosylceramide (α-GalCer) have shown promise in several clinical trials conducted in patients with cancer or viral diseases, current i NKT cell-based therapies are far from effective. The concomitant targeting of T cell receptors (TCRs) and costimulatory molecules on i NKT cells represents an exciting new opportunity to optimize such therapeutic approaches. Here, we review recent advances in our understanding of i NKT cell costimulation and discuss potential treatment modalities based on the responsiveness of i NKT cells to disease-tailored glycolipids and select costimulatory ligands.</description><identifier>ISSN: 1471-4914</identifier><identifier>EISSN: 1471-499X</identifier><identifier>DOI: 10.1016/j.molmed.2010.10.007</identifier><identifier>PMID: 21087900</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Antigens, Differentiation - genetics ; Antigens, Differentiation - immunology ; Cancer ; Clinical trials ; Costimulator ; galactosylceramide ; Gene Expression Regulation - immunology ; Glycolipids ; Humans ; Immunomodulation ; Immunotherapy ; Lymphocyte Activation - immunology ; Lymphocytes T ; Natural killer cells ; Natural Killer T-Cells - immunology ; Pathology ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins - immunology ; Reviews ; Signal Transduction - genetics ; Signal Transduction - immunology ; T-cell receptor</subject><ispartof>Trends in molecular medicine, 2011-02, Vol.17 (2), p.65-77</ispartof><rights>Elsevier Ltd</rights><rights>2010 Elsevier Ltd</rights><rights>Copyright © 2010 Elsevier Ltd. All rights reserved.</rights><rights>2010 Elsevier Ltd. All rights reserved. 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-4f6f696e68730def0ed49bdf3d8c62b487f76270df692a789f8dd7576ebc290e3</citedby><cites>FETCH-LOGICAL-c549t-4f6f696e68730def0ed49bdf3d8c62b487f76270df692a789f8dd7576ebc290e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1471491410001619$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21087900$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van den Heuvel, Marianne J</creatorcontrib><creatorcontrib>Garg, Nitan</creatorcontrib><creatorcontrib>Van Kaer, Luc</creatorcontrib><creatorcontrib>Haeryfar, S.M. Mansour</creatorcontrib><title>NKT cell costimulation: experimental progress and therapeutic promise</title><title>Trends in molecular medicine</title><addtitle>Trends Mol Med</addtitle><description>Invariant natural killer T ( i NKT) cells are innate lymphocytes with unique specificity for glycolipid antigens and remarkable immunomodulatory properties. The role of costimulatory interactions in i NKT cell responses has recently come under scrutiny. Although i NKT cells and their prototype glycolipid agonist α-galactosylceramide (α-GalCer) have shown promise in several clinical trials conducted in patients with cancer or viral diseases, current i NKT cell-based therapies are far from effective. The concomitant targeting of T cell receptors (TCRs) and costimulatory molecules on i NKT cells represents an exciting new opportunity to optimize such therapeutic approaches. Here, we review recent advances in our understanding of i NKT cell costimulation and discuss potential treatment modalities based on the responsiveness of i NKT cells to disease-tailored glycolipids and select costimulatory ligands.</description><subject>Animals</subject><subject>Antigens, Differentiation - genetics</subject><subject>Antigens, Differentiation - immunology</subject><subject>Cancer</subject><subject>Clinical trials</subject><subject>Costimulator</subject><subject>galactosylceramide</subject><subject>Gene Expression Regulation - immunology</subject><subject>Glycolipids</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>Immunotherapy</subject><subject>Lymphocyte Activation - immunology</subject><subject>Lymphocytes T</subject><subject>Natural killer cells</subject><subject>Natural Killer T-Cells - immunology</subject><subject>Pathology</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins - immunology</subject><subject>Reviews</subject><subject>Signal Transduction - genetics</subject><subject>Signal Transduction - immunology</subject><subject>T-cell receptor</subject><issn>1471-4914</issn><issn>1471-499X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk1v1DAQtRCIlsI_QCg3TruMncQfHJBQVQpqBQeKxM3y2pPWixMHO6nov6_DtsvHpSdbM2-e3_MbQl5SWFOg_M123cfQo1sz-F1aA4hH5JA2gq4apb4_3t9pc0Ce5bwFoK0Q8ik5YBSkUACH5OTz2UVlMYTKxjz5fg5m8nF4W-GvEZPvcZhMqMYULxPmXJnBVdMVJjPiPHm7NHqf8Tl50pmQ8cXdeUS-fTi5OP64Ov9y-un4_fnKto2aVk3HO644cilqcNgBukZtXFc7aTnbNFJ0gjMBrqCYEVJ10jnRCo4byxRgfUTe7XjHeVOs26IumaDHItSkGx2N1_92Bn-lL-O1rjnltWKF4PUdQYo_Z8yTLvIX-2bAOGetQFAOjNEHkbKlomUgF2SzQ9oUc07Y7fVQ0EtUeqt3UeklqqVaoipjr_72sh-6z-aPWSw_eu0x6Ww9DhadT2gn7aJ_6IX_CWzwg7cm_MAbzNs4p6GkpanOTIP-uqzLsi0UyqZwqupbecm9aQ</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>van den Heuvel, Marianne J</creator><creator>Garg, Nitan</creator><creator>Van Kaer, Luc</creator><creator>Haeryfar, S.M. Mansour</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20110201</creationdate><title>NKT cell costimulation: experimental progress and therapeutic promise</title><author>van den Heuvel, Marianne J ; Garg, Nitan ; Van Kaer, Luc ; Haeryfar, S.M. Mansour</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-4f6f696e68730def0ed49bdf3d8c62b487f76270df692a789f8dd7576ebc290e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Antigens, Differentiation - genetics</topic><topic>Antigens, Differentiation - immunology</topic><topic>Cancer</topic><topic>Clinical trials</topic><topic>Costimulator</topic><topic>galactosylceramide</topic><topic>Gene Expression Regulation - immunology</topic><topic>Glycolipids</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>Immunotherapy</topic><topic>Lymphocyte Activation - immunology</topic><topic>Lymphocytes T</topic><topic>Natural killer cells</topic><topic>Natural Killer T-Cells - immunology</topic><topic>Pathology</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins - immunology</topic><topic>Reviews</topic><topic>Signal Transduction - genetics</topic><topic>Signal Transduction - immunology</topic><topic>T-cell receptor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van den Heuvel, Marianne J</creatorcontrib><creatorcontrib>Garg, Nitan</creatorcontrib><creatorcontrib>Van Kaer, Luc</creatorcontrib><creatorcontrib>Haeryfar, S.M. Mansour</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Trends in molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van den Heuvel, Marianne J</au><au>Garg, Nitan</au><au>Van Kaer, Luc</au><au>Haeryfar, S.M. Mansour</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NKT cell costimulation: experimental progress and therapeutic promise</atitle><jtitle>Trends in molecular medicine</jtitle><addtitle>Trends Mol Med</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>17</volume><issue>2</issue><spage>65</spage><epage>77</epage><pages>65-77</pages><issn>1471-4914</issn><eissn>1471-499X</eissn><abstract>Invariant natural killer T ( i NKT) cells are innate lymphocytes with unique specificity for glycolipid antigens and remarkable immunomodulatory properties. The role of costimulatory interactions in i NKT cell responses has recently come under scrutiny. Although i NKT cells and their prototype glycolipid agonist α-galactosylceramide (α-GalCer) have shown promise in several clinical trials conducted in patients with cancer or viral diseases, current i NKT cell-based therapies are far from effective. The concomitant targeting of T cell receptors (TCRs) and costimulatory molecules on i NKT cells represents an exciting new opportunity to optimize such therapeutic approaches. Here, we review recent advances in our understanding of i NKT cell costimulation and discuss potential treatment modalities based on the responsiveness of i NKT cells to disease-tailored glycolipids and select costimulatory ligands.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>21087900</pmid><doi>10.1016/j.molmed.2010.10.007</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-4914 |
| ispartof | Trends in molecular medicine, 2011-02, Vol.17 (2), p.65-77 |
| issn | 1471-4914 1471-499X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3616392 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Antigens, Differentiation - genetics Antigens, Differentiation - immunology Cancer Clinical trials Costimulator galactosylceramide Gene Expression Regulation - immunology Glycolipids Humans Immunomodulation Immunotherapy Lymphocyte Activation - immunology Lymphocytes T Natural killer cells Natural Killer T-Cells - immunology Pathology Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - immunology Reviews Signal Transduction - genetics Signal Transduction - immunology T-cell receptor |
| title | NKT cell costimulation: experimental progress and therapeutic promise |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T18%3A42%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NKT%20cell%20costimulation:%20experimental%20progress%20and%20therapeutic%20promise&rft.jtitle=Trends%20in%20molecular%20medicine&rft.au=van%20den%20Heuvel,%20Marianne%20J&rft.date=2011-02-01&rft.volume=17&rft.issue=2&rft.spage=65&rft.epage=77&rft.pages=65-77&rft.issn=1471-4914&rft.eissn=1471-499X&rft_id=info:doi/10.1016/j.molmed.2010.10.007&rft_dat=%3Cproquest_pubme%3E907160221%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=851752081&rft_id=info:pmid/21087900&rft_els_id=S1471491410001619&rfr_iscdi=true |